Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1Journal of Clinical Oncology.  37:3050-3058. 2019
2019 UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line XenograftsTranslational Oncology.  12:1364-1374. 2019
2019 Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistanceOncogene.  38:6159-6171. 2019
2019 The Impact of Early Corticosteroid Pretreatment Before Initiation of Chemotherapy in Patients With Primary Central Nervous System LymphomaNeurosurgery.  85:264-272. 2019
2019 SUMOylation in glioblastoma: A novel therapeutic targetInternational Journal of Molecular Sciences.  20. 2019
2019 SUMOylation promotes survival and integration of neural stem cell grafts in ischemic strokeEBioMedicine.  42:214-224. 2019
2019 Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain TumorsWorld Neurosurgery.  122:e1592-e1598. 2019
2019 Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesisJournal of Neuro-Oncology.  141:289-301. 2019
2019 Artificial intelligence in the management of glioma: Era of personalized medicineFrontiers in Oncology.  9. 2019
2019 Roseamonas gilardii Bacteremia in a Patient with HbSβ0-thalassemia: Clinical Implications and Literature ReviewJournal of Pediatric Hematology/Oncology2019
2019 Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of miceCancer Gene Therapy2019
2019 Treatment-induced remission of medulloblastoma using a chemotherapeutic regimen devoid of vincristine in a child with charcot–marie–tooth diseaseCurrent Oncology.  26:e266-e269. 2019
2018 Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 ExpressionScientific Reports.  8. 2018
2018 FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived XenograftsScientific Reports.  8. 2018
2018 UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenograftsJournal of Neuro-Oncology.  140:209-224. 2018
2018 Quality Initiative to Improve time to Antibiotics for Febrile Pediatric Patients with Potential Neutropenia.Pediatric Quality and Safety.  3:e095. 2018
2018 Drugging SUMOylation for neuroprotection and oncotherapyNeural Regeneration Research.  13:415-416. 2018
2018 Cerebral ischemia increases small ubiquitin-like modifier conjugation within human penumbral tissue: Radiological-pathological correlationFrontiers in Neurology.  8. 2018
2017 Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002Molecular Therapy - Oncolytics.  7:27-36. 2017
2017 Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literatureMedical and Pediatric Oncology.  64. 2017
2017 Publication outcomes of abstracts from the American Society of Hematology Annual MeetingAmerican Journal of Hematology.  92:E81-E83. 2017
2017 Oncolytic Virotherapy for the Treatment of Malignant GliomaNeurotherapeutics.  14:333-344. 2017
2017 Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain TumorsHuman Gene Therapy Clinical Development.  28:7-16. 2017
2017 Checkpoint proteins in pediatric brain and extracranial solid tumors: Opportunities for immunotherapyClinical Cancer Research.  23:342-350. 2017
2017 Combination strategies enhance oncolytic virotherapyOncotarget.  8:34020-34021. 2017
2016 Protocol for Reducing Time to Antibiotics in Pediatric Patients Presenting to an Emergency Department with Feer and Neutropenia: Efficacy and BarriersPediatric Emergency Care.  32:739-745. 2016
2016 Effect of repeat dosing of engineered oncolytic herpes simplex virus on preclinical models of rhabdomyosarcomaTranslational Oncology.  9:419-430. 2016
2016 Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex virusesNeuro-Oncology.  18:227-235. 2016
2016 Oncolytic virotherapy for pediatric malignancies: future prospects.Oncolytic Virotherapy.  5:73-80. 2016
2015 Pediatric cancer gone viral. Part I: Strategies for utilizing oncolytic herpes simplex virus-1 in childrenMolecular Therapy - Oncolytics.  2:15015. 2015
2015 Pediatric cancer gone viral. Part II: Potential clinical application of oncolytic herpes simplex virus-1 in childrenMolecular Therapy - Oncolytics.  2:15016. 2015
2015 Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomasJournal of Neuro-Oncology.  122:585-593. 2015
2015 Attack of the cancer-killing viruses: Clinical application of oncolytic virotherapy in childrenMedical and Pediatric Oncology.  62:739-740. 2015
2015 γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxiaGene Therapy.  22:348-355. 2015
2014 Oncolytic viral therapy: targeting cancer stem cells.Oncolytic Virotherapy.  2014:21-33. 2014
2014 Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumorsPLoS ONE.  9. 2014
2014 Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitroJournal of Neuro-Oncology.  118:61-72. 2014
2014 The role of Src family kinases in growth and migration of glioma stem cellsInternational Journal of Oncology.  45:302-310. 2014
2013 Pediatric glioma stem cells: Biologic strategies for oncolytic HSV virotherapyFrontiers in Oncology.  3 FEB. 2013
2013 Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of NeuroblastomaPLoS ONE.  8. 2013
2013 Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resectionJournal of Pediatric Hematology/Oncology.  35. 2013
2013 CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSVMedical and Pediatric Oncology.  60:45-52. 2013
2012 Hypoxia moderates γ134.5-deleted herpes simplex virus oncolytic activity in human glioma xenoline primary culturesTranslational Oncology.  5:200-207. 2012
2012 Targeting pediatric cancer stem cells with oncolytic virotherapy.Pediatric Research.  71:500-510. 2012
2011 Response to radiation in renal medullary carcinomaRare Tumors.  3:100-103. 2011
2011 Long-term complete response after treatment with cytarabine, vincristine, and prednisone in an infant with refractory multisystem Langerhans cell histiocytosisMedical and Pediatric Oncology.  57:180-181. 2011
2011 Cancer stem cells and pediatric solid tumorsCancers.  3:298-318. 2011
2010 Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinomaMedical and Pediatric Oncology.  55:1217-1220. 2010
2009 Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111Journal of Neuro-Oncology.  95:199-209. 2009
2009 Herpes simplex virus oncolytic therapy for pediatric malignanciesMolecular Therapy.  17:1125-1135. 2009
2008 Myelofibrosis in a patient with familial hemophagocytic lymphohistiocytosisMedical and Pediatric Oncology.  50:1260-1262. 2008
2007 Changing trends of research and treatment in infant neuroblastomaMedical and Pediatric Oncology.  49:1060-1065. 2007

Principal Investigator On

  • Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2024
  • ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • Headstart IV Clinical Study Rider  awarded by NATIONWIDE CHILDREN'S 2017 - 2022
  • Ph1 Study of HSV G207 in Pediatric Malignant Cerebellar Tumors IND 16294 01/05/18  awarded by Food & Drug Administration 2019 - 2022
  • Phase 1 Trial of Engineered HSV G207 in Children with Malignant Cerebellar Brain Tumors  awarded by CANNONBALL KIDS' CANCER FOUNDATION 2019 - 2022
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • Overcoming Myeloid Cell-Mediated Immunosuppression to Enhance Immunovirotherapy  awarded by HYUNDAI HOPE ON WHEELS 2019 - 2021
  • Maximizing the Anti-Tumor Immune Response from HSV Immunovirotherapy  awarded by RALLY FOUNDATION 2019 - 2021
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2020
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • NIH COG Phase I Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND16294 (12/10/14)  awarded by Food & Drug Administration 2016 - 2020
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • lmmunovirotherapy to Target Pediatric Brain Tumors  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2018 - 2020
  • Expansion of G207 Trial  awarded by CANNONBALL KIDS' CANCER FOUNDATION 2017 - 2020
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Intraventricular Delivery of Engineered Oncolytic Herpes Simplex Virotherapy to Treat Localized and Metastatic Pediatric Brain Tumors  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2015 - 2019
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Pilot Study of HSV G207 Alone or with Radiation in Children with Recurrent Brain Tumors  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2015 - 2018
  • Enhancement of lmmunovirotherapy with IDO Inhibition in Pediatric Medulloblastoma  awarded by HYUNDAI HOPE ON WHEELS 2016 - 2018
  • Immune Checkpoint Blockade in Combination with oHSVs for Pediatric Brain Tumors  awarded by American Brain Tumor Association 2018
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2016 - 2017
  • Engineered Oncolytic Herpes Simplex Virotherapy for Medulloblastomas  awarded by St. Baldrick's Foundation 2012 - 2017
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2015 - 2016
  • Evaluation pf Clinically-ready Oncolytic HSV in Pediatric Brain Tumors  awarded by HYUNDAI HOPE ON WHEELS 2013 - 2015
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2014 - 2015
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2013 - 2014
  • Preclinical Testing of Engineered Herpes Simplex Virotherapy in Pediatric Brain Tumors  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2011 - 2013
  • Preclinical Testing of Oncolytic Engineered Herpes Simplex Virus in Medulloblastomas  awarded by American Brain Tumor Association 2012
  • Affect of Oxygen Tension on Glioma Stem Cells  awarded by ALABAMA CHILDREN'S HOSPITAL FOUNDATION 2009 - 2011
  • Investigator On

  • LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis  awarded by St. Jude Children's Research Hospital 2019 - 2024
  • APEC1621SC - PEDIATRIC MATCH PCR - COG FOUNDATION  awarded by CHILDREN'S ONCOLOGY GROUP 2017 - 2022
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2019 - 2021
  • CTSU: Phase ll Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2021
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015 - 2020
  • Private Grant  awarded by ONCOCEUTICS INC 2019 - 2020
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2020
  • Phase 1-11 Study of MEK 162 for Children with Progressive or Recurrent Cancer and A Phase 11 Study of Children with Low- Grade Gliomas and Other Ras/ RAF/MAP Pathway Activated Tumors  awarded by CHILDREN'S HOSPITAL LA 2017 - 2020
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2018
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP 2015 - 2018
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2018
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018
  • ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2018
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • Phase I Study of MEK162 for Children with Progressive or Recurrent Cancer and a Phase II Study of Children with Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors  awarded by Childrens Hospital Los Angeles 2017 - 2018
  • Private Grant  awarded by Bayer AG 2018
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2017
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2017
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee 2015 - 2016
  • CCOP Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2015
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP 2014
  • COG Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2014
  • A Phase II Study of Sunitinib in Recurrent or Progressive Brain Tumors in Pediatric and Young Adult Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2013
  • Education And Training

  • Doctor of Medicine, Medical College of Georgia 2002
  • UAB Hospital, Internship 2003
  • UAB Hospital, Residency 2005
  • UAB Hospital, Postdoctoral Fellowship 2008
  • Full Name

  • Gregory Friedman